Department of Pharmaceutical Technology, Faculty of Pharmacy, Jordan University of Science and Technology , Irbid , Jordan.
Pharm Dev Technol. 2014 Feb;19(1):103-15. doi: 10.3109/10837450.2012.757785. Epub 2013 Jan 24.
The aim of this study is to control the dissolution rate of Venlafaxine HCl.
To prepare sustained release tablets of Venlafaxine HCl.
Different liquisolid formulations, liquid vehicles, drug concentration in the liquid medication and different ratios of carrier to coating material (R) were prepared. The prepared powders were characterized for possible interactions between drug and excipients using differential scanning calorimetry, X-ray, Fourier transform infrared analysis and scanning electron microscopy. Powder flowability was also evaluated, then they are compressed at different compression forces, and the compressed tablets were evaluated for their mechanical properties and dissolution profile.
Release results show that sustained release behavior can be obtained from liquisolid formulation containing Tween 80 as liquid vehicle.
Many factors affect the retardation effect of Venlafaxine HCl such as the type of liquid vehicle, drug concentration in the liquid medication and R. The mechanism of the in vitro release profiles was found to be mainly controlled by diffusion and polymer relaxation.
Sustained release formulation of Venlafaxine HCl was attained using the liquisolid technique.
本研究旨在控制盐酸文拉法辛的溶出速率。
制备盐酸文拉法辛的缓释片。
制备不同的液质体配方、液体制剂、药物在液体制剂中的浓度和不同的载体与包衣材料的比例（R）。使用差示扫描量热法、X 射线、傅里叶变换红外分析和扫描电子显微镜对所制备的粉末进行了可能的药物与赋形剂相互作用的表征。还评估了粉末的流动性，然后在不同的压缩力下进行压缩，对压缩片进行机械性能和溶出度评价。
释放结果表明，含有吐温 80 作为液体载体的液质体配方可以获得缓释行为。
许多因素影响盐酸文拉法辛的延迟效果，如液体载体的类型、液体制剂中的药物浓度和 R。体外释放曲线的机制被发现主要由扩散和聚合物弛豫控制。
采用液质体技术获得了盐酸文拉法辛的缓释制剂。
